TSCAN THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Warrant Issued
TSCAN THERAPEUTICS, INC. (TCRX) reported Adjustments to Additional Paid in Capital, Warrant Issued of $158.07 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-03-04
- TSCAN THERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-12-31 was $29.80M.
- TSCAN THERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-09-30 was $0.00.
- TSCAN THERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-06-30 was $128.27M, a 38.95% increase year-over-year.
- TSCAN THERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-12-31 was $0.00.
- TSCAN THERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for fiscal 2024 was $158.07M, a 71.22% increase from fiscal 2023.
- TSCAN THERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for fiscal 2023 was $92.32M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2024-12-31 | $29.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $29.80M derived: sum of 2 quarters · filed 2026-03-04 | $158.07M derived: sum of 3 quarters · filed 2026-03-04 | $158.07M 10-K · filed 2026-03-04 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $128.27M derived: sum of 2 quarters · filed 2025-11-12 | $128.27M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $128.27M 10-Q · filed 2025-08-12 | $128.27M 10-Q · filed 2025-08-12 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | $92.32M derived: sum of 3 quarters · filed 2025-03-05 | $92.32M 10-K · filed 2025-03-05 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $92.32M derived: sum of 2 quarters · filed 2024-11-12 | $92.32M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $92.32M 10-Q · filed 2024-08-12 | $92.32M 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |